Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release.

Currow, DC; Kochovska, S; Ferreira, D; Johnson, M

Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release.

Currow, DC Kochovska, S

Ferreira, D Johnson, M

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Journal Article
Citation:: Current opinion in supportive and palliative care, 2020, 14, (3), pp. 177-181
Issue Date:: 2020-09

In Progress

	Filename	Description	Size
	Morphine for the symptomatic reduction of chronic breathlessess - the case for controlled release_Author's Copy.pdf	Accepted Manuscript	397.99 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is being processed and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Currow, DC
dc.contributor.author	Kochovska, S https://orcid.org/0000-0002-3531-0389
dc.contributor.author	Ferreira, D
dc.contributor.author	Johnson, M
dc.date.accessioned	2021-03-01T03:21:27Z
dc.date.available	2021-03-01T03:21:27Z
dc.date.issued	2020-09
dc.identifier.citation	Current opinion in supportive and palliative care, 2020, 14, (3), pp. 177-181
dc.identifier.issn	1751-4258
dc.identifier.issn	1751-4266
dc.identifier.uri	http://hdl.handle.net/10453/146556
dc.description.abstract	<h4>Purpose of review</h4>Clinicians who seek to reduce the symptomatic burden of chronic breathlessness by initiating regular low-dose morphine has the choice of immediate or sustained-release formulations - which will be better for this often frail population, and which has the more robust evidence to inform its prescription? Both formulations can be used.<h4>Recent findings</h4>For chronic breathlessness, three factors consistently favour the use of regular, low-dose, sustained-release morphine over immediate-release formulations: SUMMARY: As the evidence base expands for the symptomatic reduction of chronic breathlessness, pharmacological interventions will play a part. Using the best available evidence underpins patient-centred approaches that seek to predictably maximize the net effect.As such, the weight of evidence in patient-centred clinical care favours the use of regular, low-dose sustained-release morphine for the symptomatic reduction of chronic breathlessness.
dc.format	Print
dc.language	eng
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	Current opinion in supportive and palliative care
dc.relation.isbasedon	10.1097/spc.0000000000000520
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Morphine for the symptomatic reduction of chronic breathlessness: the case for controlled release.
dc.type	Journal Article
utslib.citation.volume	14
utslib.location.activity	United States
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	in_progress	*
dc.date.updated	2021-03-01T03:21:22Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	14
utslib.citation.issue	3

Abstract:

Purpose of review

Clinicians who seek to reduce the symptomatic burden of chronic breathlessness by initiating regular low-dose morphine has the choice of immediate or sustained-release formulations - which will be better for this often frail population, and which has the more robust evidence to inform its prescription? Both formulations can be used.

Recent findings

For chronic breathlessness, three factors consistently favour the use of regular, low-dose, sustained-release morphine over immediate-release formulations: SUMMARY: As the evidence base expands for the symptomatic reduction of chronic breathlessness, pharmacological interventions will play a part. Using the best available evidence underpins patient-centred approaches that seek to predictably maximize the net effect.As such, the weight of evidence in patient-centred clinical care favours the use of regular, low-dose sustained-release morphine for the symptomatic reduction of chronic breathlessness.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/146556